Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 26, 2024
Deals
Sarepta broadens pipeline via siRNA deal with Arrowhead, paying $825M up front
CEO Ingram sees “the one significant strategic transaction” to transform Sarepta’s future, while Arrowhead preps for first-ever launch
BioCentury | Mar 3, 2023
Discovery & Translation
Sanofi’s macrolide antibiotic for TB; organoid-based target discovery for steatosis and more
BioCentury’s roundup of translational news
BioCentury | Feb 15, 2023
Deals
Feb. 15 Quick Takes: Emergent deal to grow Bavarian Nordic footprint in U.S., Europe
Plus: Maxion raises series A to develop mAbs against ion channels, GPCRs and updates from Arrowhead, Moderna, Galera, Codagenix, Nanite
BioCentury | Dec 8, 2021
Deals
Eyeing pair of amyloidosis indications, AZ in deal for Ionis asset
AZ pays $200M up front for ‘immediate’ opportunity in one indication, larger population in another
BioCentury | Nov 24, 2020
Product Development
Nov. 24 Quick Takes: Elevian raises $15M; plus AZ-Ionis, Genmab, Moderna and Novartis
Anti-aging play Elevian raises $15M equity roundElevian Inc. raised $15 million in an equity financing led by Prime Movers Lab. Also participating were Bold Capital Partners, For Good Ventures, Kizoo
Items per page:
1 - 7 of 7